Literature DB >> 16705126

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Andrew J Stephenson1, Peter T Scardino, James A Eastham, Fernando J Bianco, Zohar A Dotan, Paul A Fearn, Michael W Kattan.   

Abstract

An existing preoperative nomogram predicts the probability of prostate cancer recurrence, defined by prostate-specific antigen (PSA), at 5 years after radical prostatectomy based on clinical stage, serum PSA, and biopsy Gleason grade. In an updated and enhanced nomogram, we have extended the predictions to 10 years, added the prognostic information of systematic biopsy results, and enabled the predictions to be adjusted for the year of surgery. Cox regression analysis was used to model the clinical information for 1978 patients treated by two high-volume surgeons from our institution. The nomogram was externally validated on an independent cohort of 1545 patients with a concordance index of 0.79 and was well calibrated with respect to observed outcome. The inclusion of the number of positive and negative biopsy cores enhanced the predictive accuracy of the model. Thus, a new preoperative nomogram provides robust predictions of prostate cancer recurrence up to 10 years after radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705126      PMCID: PMC2242430          DOI: 10.1093/jnci/djj190

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

1.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

2.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

3.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.

Authors:  Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

5.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

6.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

7.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

8.  Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.

Authors:  James A Eastham; Michael W Kattan; Elyn Riedel; Colin B Begg; Thomas M Wheeler; Claudia Gerigk; Mithat Gonen; Victor Reuter; Peter T Scardino
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

9.  Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure).

Authors:  Kirsten L Greene; Maxwell V Meng; Eric P Elkin; Matthew R Cooperberg; David J Pasta; Michael W Kattan; Katrine Wallace; Peter R Carroll
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.

Authors:  Michael W Kattan; James A Eastham; Thomas M Wheeler; Norio Maru; Peter T Scardino; Andreas Erbersdobler; Markus Graefen; Hartwig Huland; Hideshige Koh; Shahrokh F Shariat; Kevin M Slawin; Makoto Ohori
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

View more
  169 in total

1.  Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur.

Authors:  François Audenet; Elise Seringe; Sarah J Drouin; Eva Comperat; Olivier Cussenot; Marc-Olivier Bitker; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-06-03       Impact factor: 4.226

2.  Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.

Authors:  Andrew J Vickers; Caroline J Savage; Fernando J Bianco; Eric A Klein; Michael W Kattan; Fernando P Secin; Bertrand D Guilloneau; Peter T Scardino
Journal:  Int J Cancer       Date:  2010-06-09       Impact factor: 7.396

Review 3.  The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.

Authors:  Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman
Journal:  BJU Int       Date:  2010-03-15       Impact factor: 5.588

4.  Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study.

Authors:  Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger
Journal:  World J Urol       Date:  2010-12-30       Impact factor: 4.226

5.  Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?

Authors:  S B Stewart; C D Scales; J W Moul; S D Reed
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-10       Impact factor: 5.554

6.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

7.  Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

Authors:  Zachary Klaassen; Abhay A Singh; Lauren E Howard; Zhaoyong Feng; Bruce Trock; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Alan Partin; Misop Han; Stephen J Freedland
Journal:  Cancer       Date:  2014-12-09       Impact factor: 6.860

8.  Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

Authors:  Jonathan L Silberstein; Stephen A Poon; Daniel D Sjoberg; Alexandra C Maschino; Andrew J Vickers; Aaron Bernie; Badrinath R Konety; W Kevin Kelly; James A Eastham
Journal:  BJU Int       Date:  2015-04-17       Impact factor: 5.588

Review 9.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

Review 10.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.